Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sunitinib × Genitourinary × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3 Lymphoid 3 Sarcoma 2 Gastrointestinal 2 NET 1 Genitourinary 1 Endocrine 1 Dermatologic 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 58 Specimen Handling 54 pembrolizumab 38 enzalutamide 30 Nivolumab 28 Gemcitabine 27 Prednisone 25 Abiraterone Acetate 24 Biopsy 22 Docetaxel 20 apalutamide 19 Androgen Antagonists 19 Ipilimumab 18 darolutamide 17 Cisplatin 17 cabozantinib 16 Radiotherapy 16 enfortumab vedotin 15 X-Rays 15 Carboplatin 15 Radiosurgery 13 Pluvicto 12 Leuprolide 12 atezolizumab 10 abiraterone 10 Radiation 10 cabazitaxel 9 avelumab 9 Photons 9 Immunoglobulin G 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡